myChoice CDx
A tumour test that measures DNA-repair scarring so that women with ovarian cancer beyond BRCA carriers can benefit from PARP inhibitors.
Overview
Approved 23 October 2019 (PMA P190014) with niraparib for homologous-recombination-deficient ovarian cancer after several lines of therapy, and in May 2020 as the companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer (PAOLA-1). Roughly half of high-grade serous ovarian cancers are HRD-positive by this definition, about twice the BRCA-mutated fraction. The scar is permanent, so a tumour can remain HRD-positive after it has developed resistance, one reason the test predicts benefit better in first-line than in later lines.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2019 | Companion diagnostic for niraparib in HRD-positive advanced ovarian cancer |
| US | 2020 | Companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Notes
top- What a result means: HRD-positive (by genomic instability score or BRCA mutation) means adding a PARP inhibitor after chemotherapy is likely to delay relapse; HRD-negative means the benefit is much smaller.
Latest papers
topQuery for this drug: (TITLE:"myChoice CDx" OR ABSTRACT:"myChoice CDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about myChoice CDx, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductBRACAnalysis CDx
Shares Myriad Genetics, HRD & BRCA testing, Companion diagnostics, Olaparib and the tag test.
- ProductEndoPredict
Shares Myriad Genetics and the tag test.
- ProductProlaris
Shares Myriad Genetics and the tag test.
- ProductResolution ctDx FIRST
Shares Companion diagnostics and the tag test.
- ProductMI Cancer Seek
Shares Companion diagnostics and the tag test.
- Productcobas EGFR Mutation Test v2
Shares Companion diagnostics and the tag test.
- ProductTempus xT CDx
Shares Companion diagnostics and the tag test.
- ProductTruSight Oncology Comprehensive
Shares Companion diagnostics and the tag test.